National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management

On January 9th, 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9th, 2020,...

Full description

Saved in:

Bibliographic Details
Published in:	Infectious disease reports Vol. 12; no. 1; p. 8543
Main Authors:	Nicastri, Emanuele, Petrosillo, Nicola, Ascoli Bartoli, Tommaso, Lepore, Luciana, Mondi, Annalisa, Palmieri, Fabrizio, D’Offizi, Gianpiero, Marchioni, Luisa, Murachelli, Silvia, Ippolito, Giuseppe, Antinori for ICOTREG, Andrea
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 17.03.2020 PAGEPress Publications, Pavia, Italy
Subjects:	Coronaviruses COVID-19 Expert Opinion Infectious diseases Pandemics Patients Public health SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Treatment Viral diseases COVID-19 SARS-CoV-2 Treatment
ISSN:	2036-7449, 2036-7430, 2036-7449
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	On January 9th, 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9th, 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; these recomendations should be considered as expert opinions, which may be modified according to newly produced literature data. *for the INMI COVID-19 Treatment Group – ICOTREG Abdeddaim A, Agrati C, Albarello F, Antinori A, Ascoli Bartoli T, Baldini F, Bellagamba R, Bevilacqua N, Bibas M, Biava G, Boumis E, Busso D, Camici M, Capobianchi MR, Capone A, Caravella I, Cataldo A, Cerilli S, Chinello G, Cicalini S, Corpolongo A, Cristofaro M, D’Abramo A, Dantimi C, De Angelis G, De Palo MG, D’Offizi G, De Zottis F, Di Lorenzo R, Di Stefano F, Fusetti M, Galati V, Gagliardini R, Garotto G, Gebremeskel Tekle Saba, Giancola ML, Giansante F, Girardi E, Goletti D, Granata G, Greci MC, Grilli E, Grisetti S, Gualano G, Iacomi F, Iannicelli G, Ippolito G, Lepore L, Libertone R, Lionetti R, Liuzzi G, Loiacono L, Macchione M, Marchioni L, Mariano A, Marini MC, Maritti M, Mastrobattista A, Mazzotta V, Mencarini P, Migliorisi-Ramazzini P, Mondi A, Montalbano M, Mosti S, Murachelli S, Musso M, Nicastri E, Noto P, Oliva A, Palazzolo C, Palmieri F, Pareo C, Petrone A, Pianura E, Pinnetti C, Pontarelli A, Puro V, Rianda A, Rosati S, Sampaolesi A, Santagata C, Scarcia D’Aprano S, Scarabello A, Schininà V, Scorzolini L, Stazi GV, Taibi C, Taglietti F, Tonnarini R, Topino S, Vergori A, Vincenzi L, Visco-Comandini U, Vittozzi P, Zaccarelli M, Zaccaro G.
AbstractList	On January 9th, 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9th, 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; these recomendations should be considered as expert opinions, which may be modified according to newly produced literature data. *for the INMI COVID-19 Treatment Group – ICOTREG Abdeddaim A, Agrati C, Albarello F, Antinori A, Ascoli Bartoli T, Baldini F, Bellagamba R, Bevilacqua N, Bibas M, Biava G, Boumis E, Busso D, Camici M, Capobianchi MR, Capone A, Caravella I, Cataldo A, Cerilli S, Chinello G, Cicalini S, Corpolongo A, Cristofaro M, D’Abramo A, Dantimi C, De Angelis G, De Palo MG, D’Offizi G, De Zottis F, Di Lorenzo R, Di Stefano F, Fusetti M, Galati V, Gagliardini R, Garotto G, Gebremeskel Tekle Saba, Giancola ML, Giansante F, Girardi E, Goletti D, Granata G, Greci MC, Grilli E, Grisetti S, Gualano G, Iacomi F, Iannicelli G, Ippolito G, Lepore L, Libertone R, Lionetti R, Liuzzi G, Loiacono L, Macchione M, Marchioni L, Mariano A, Marini MC, Maritti M, Mastrobattista A, Mazzotta V, Mencarini P, Migliorisi-Ramazzini P, Mondi A, Montalbano M, Mosti S, Murachelli S, Musso M, Nicastri E, Noto P, Oliva A, Palazzolo C, Palmieri F, Pareo C, Petrone A, Pianura E, Pinnetti C, Pontarelli A, Puro V, Rianda A, Rosati S, Sampaolesi A, Santagata C, Scarcia D’Aprano S, Scarabello A, Schininà V, Scorzolini L, Stazi GV, Taibi C, Taglietti F, Tonnarini R, Topino S, Vergori A, Vincenzi L, Visco-Comandini U, Vittozzi P, Zaccarelli M, Zaccaro G. On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The " " National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data. On January 9 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; these recomendations should be considered as expert opinions, which may be modified according to newly produced literature data. On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data. On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The "L. Spallanzani" National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data.On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The "L. Spallanzani" National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data.
Author	Palmieri, Fabrizio Ippolito, Giuseppe Nicastri, Emanuele Petrosillo, Nicola D’Offizi, Gianpiero Lepore, Luciana Antinori for ICOTREG, Andrea Ascoli Bartoli, Tommaso Mondi, Annalisa Murachelli, Silvia Marchioni, Luisa
AuthorAffiliation	National Institute for Infectious Diseases “L. Spallanzani” , IRCCS, Rome, Italy
AuthorAffiliation_xml	– name: National Institute for Infectious Diseases “L. Spallanzani” , IRCCS, Rome, Italy
Author_xml	– sequence: 1 givenname: Emanuele surname: Nicastri fullname: Nicastri, Emanuele – sequence: 2 givenname: Nicola orcidid: 0000-0002-2585-7567 surname: Petrosillo fullname: Petrosillo, Nicola – sequence: 3 givenname: Tommaso surname: Ascoli Bartoli fullname: Ascoli Bartoli, Tommaso – sequence: 4 givenname: Luciana surname: Lepore fullname: Lepore, Luciana – sequence: 5 givenname: Annalisa surname: Mondi fullname: Mondi, Annalisa – sequence: 6 givenname: Fabrizio surname: Palmieri fullname: Palmieri, Fabrizio – sequence: 7 givenname: Gianpiero surname: D’Offizi fullname: D’Offizi, Gianpiero – sequence: 8 givenname: Luisa surname: Marchioni fullname: Marchioni, Luisa – sequence: 9 givenname: Silvia surname: Murachelli fullname: Murachelli, Silvia – sequence: 10 givenname: Giuseppe surname: Ippolito fullname: Ippolito, Giuseppe – sequence: 11 givenname: Andrea surname: Antinori for ICOTREG fullname: Antinori for ICOTREG, Andrea
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/32218915$$D View this record in MEDLINE/PubMed
BookMark	eNptksFu1DAQhiNUREvpkSuKxIVLFjt2YvuChFIKKy1UaoGrNXHGW6-y8dbOIlEufRB4uT4J3t0WtRW-2Jr5_c3Y_zzP9gY_YJa9pGTCiaRvXRcmJSnJRFacPckOSsLqQnCu9u6d97OjGBckLaZqLtizbJ-VJZWKVgfZry8wOj9An0-HOLpxPWJufcjHC0wRiyZl1zE_dhEhYsxvrn_PJvn5CvoehisY3M31n3x61jTnk_wMjV8ucei2yLjlNKffp8cFVXnTu8GZVOczDDDHJBtfZE8t9BGPbvfD7NvJh6_Np2J2-nHavJ8VppL1WPCWYolGYFVLYVvREgJQlRwqAjUjjEtplLAS6haVIVKYjpJalQTaurPYssNsuuN2HhZ6FdwSwk_tweltwIe5hjA606NurSXAKDVSCl5xkGCMsQRVrcCqqkqsdzvWat0usTPpGQH6B9CHmcFd6Ln_oQVRQjKWAG9uAcFfrjGOeumiwc13YvppXTLJS5q82tR6_Ui68OuQvEoqzgSjIrmeVK_ud_SvlTuPk4DtBCb4GANabdy4tSg16HpNid4Mk07DpDfDpOUOWzy6dQf-v_4v8G_NCw
CitedBy_id	crossref_primary_10_1016_j_jiph_2022_12_019 crossref_primary_10_1186_s12967_021_02938_8 crossref_primary_10_15342_ijms_7_172 crossref_primary_10_3389_fimmu_2022_920227 crossref_primary_10_1007_s10067_020_05160_x crossref_primary_10_1016_j_oraloncology_2020_105043 crossref_primary_10_1186_s13054_020_03422_3 crossref_primary_10_3390_antiox10060881 crossref_primary_10_1016_j_ijid_2021_04_034 crossref_primary_10_1039_D4BM00224E crossref_primary_10_1186_s13317_020_00141_1 crossref_primary_10_2147_DDDT_S320320 crossref_primary_10_1093_ofid_ofab376 crossref_primary_10_1016_j_ijantimicag_2020_106078 crossref_primary_10_1177_08971900211000691 crossref_primary_10_1186_s40001_021_00591_x crossref_primary_10_1007_s00296_020_04663_9 crossref_primary_10_3390_molecules29235564 crossref_primary_10_1080_14712598_2020_1789097 crossref_primary_10_3390_healthcare10091780 crossref_primary_10_3904_kjim_2020_417 crossref_primary_10_1016_j_fct_2021_112087 crossref_primary_10_5144_0256_4947_2020_365 crossref_primary_10_1007_s10067_020_05179_0 crossref_primary_10_1007_s00296_020_04570_z crossref_primary_10_1016_j_heliyon_2021_e08496 crossref_primary_10_1016_j_trac_2020_116051 crossref_primary_10_3389_fimmu_2020_01439 crossref_primary_10_1080_00365513_2022_2034037 crossref_primary_10_3390_jcm9061668 crossref_primary_10_1016_j_jinf_2021_02_023 crossref_primary_10_1093_ofid_ofaa421 crossref_primary_10_1007_s10072_020_04486_3 crossref_primary_10_1016_j_redar_2020_08_004 crossref_primary_10_3389_fmed_2021_786414 crossref_primary_10_1016_j_phymed_2022_154191 crossref_primary_10_1016_j_surg_2020_04_036 crossref_primary_10_1007_s40620_020_00755_8 crossref_primary_10_1016_j_jclinane_2020_109926 crossref_primary_10_1016_j_fct_2021_112106 crossref_primary_10_1007_s10096_020_04063_8 crossref_primary_10_25259_SNI_191_2020 crossref_primary_10_1371_journal_pone_0247488 crossref_primary_10_1016_j_lfs_2020_118096 crossref_primary_10_1161_JAHA_120_017126 crossref_primary_10_3390_cells11010052 crossref_primary_10_1016_j_tmaid_2021_102135 crossref_primary_10_1007_s11356_021_13501_9 crossref_primary_10_4081_gh_2020_880 crossref_primary_10_3390_microorganisms9030525 crossref_primary_10_3389_fmed_2020_606429 crossref_primary_10_1016_j_jtemb_2022_126954 crossref_primary_10_2147_IDR_S306439 crossref_primary_10_3389_fsurg_2023_1059517 crossref_primary_10_1016_j_ijid_2022_07_049 crossref_primary_10_1007_s43440_020_00155_6 crossref_primary_10_1016_j_clim_2020_108414 crossref_primary_10_1007_s11547_021_01371_7 crossref_primary_10_1016_j_redare_2020_08_003 crossref_primary_10_1186_s13063_021_05675_x crossref_primary_10_1016_j_autrev_2020_102573 crossref_primary_10_1016_j_ijantimicag_2020_106201 crossref_primary_10_1111_ijlh_13229 crossref_primary_10_1016_j_medcli_2020_07_001 crossref_primary_10_1208_s12249_020_01756_3 crossref_primary_10_1136_bmjspcare_2020_002602 crossref_primary_10_12688_f1000research_36371_1 crossref_primary_10_2147_TCRM_S301817 crossref_primary_10_5858_arpa_2020_0248_LE crossref_primary_10_3389_fimmu_2022_846753 crossref_primary_10_1016_j_sjbs_2021_10_020 crossref_primary_10_1016_j_ejphar_2020_173717 crossref_primary_10_1016_j_cmi_2020_04_031 crossref_primary_10_2147_DDDT_S354841 crossref_primary_10_1016_j_neurol_2022_11_004 crossref_primary_10_1080_1744666X_2021_1847640 crossref_primary_10_2147_TCRM_S262936 crossref_primary_10_1136_annrheumdis_2020_218528 crossref_primary_10_1007_s11940_020_00641_5 crossref_primary_10_1093_ofid_ofab278 crossref_primary_10_1016_j_medcle_2020_07_009 crossref_primary_10_5694_mja2_50698 crossref_primary_10_1002_cncr_33366 crossref_primary_10_1007_s13304_020_00825_3 crossref_primary_10_1002_prot_26164 crossref_primary_10_1097_MRM_0000000000000258 crossref_primary_10_1371_journal_pone_0239389 crossref_primary_10_4103_jad_jad_9_24 crossref_primary_10_5501_wjv_v10_i6_326 crossref_primary_10_1002_cbin_11400 crossref_primary_10_3390_tropicalmed5030141 crossref_primary_10_1016_j_cbi_2021_109497 crossref_primary_10_1016_j_cytogfr_2020_06_012 crossref_primary_10_1007_s11547_020_01269_w crossref_primary_10_1007_s00330_020_07034_x crossref_primary_10_1097_APO_0000000000000289 crossref_primary_10_1136_bmjopen_2020_040129 crossref_primary_10_1097_CCE_0000000000000111 crossref_primary_10_1016_j_cmi_2020_09_051 crossref_primary_10_1016_j_ijid_2021_03_078
Cites_doi	10.1038/s41467-019-13940-6 10.1136/thorax.2003.012658 10.1002/jmv.25711 10.2147/TCRM.S150524 10.1186/1743-422X-2-69 10.1016/S2213-2600(20)30076-X 10.1056/NEJMoa2001191 10.3346/jkms.2020.35.e79 10.1001/jama.2020.1585 10.1164/rccm.201503-0584OC 10.5582/bst.2020.01047 10.1016/j.tmaid.2019.06.012 10.1016/j.ijantimicag.2020.105924 10.1016/j.ijid.2013.07.002 10.1634/theoncologist.2018-0028 10.1016/S0140-6736(20)30183-5 10.1016/S0140-6736(20)30361-5 10.1038/cr.2012.165 10.1128/mBio.00221-18 10.1093/qjmed/94.10.521 10.1093/cid/ciaa237 10.1097/PCC.0000000000000432 10.1093/infdis/jiv392
ContentType	Journal Article
Copyright	Copyright: the Author(s), 2020. 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright: the Author(s), 2020 2020 Licensee PAGEPress, Italy
Copyright_xml	– notice: Copyright: the Author(s), 2020. – notice: 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright: the Author(s), 2020 2020 Licensee PAGEPress, Italy
DBID	AAYXX CITATION NPM 3V. 7X2 7X7 7XB 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA ATCPS AZQEC BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. M0K M0S PATMY PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PYCSY 7X8 5PM DOA
DOI	10.4081/idr.2020.8543
DatabaseName	CrossRef PubMed ProQuest Central (Corporate) Agricultural Science Collection ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Natural Science Collection ProQuest One Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Agricultural Science Database Health & Medical Collection (Alumni Edition) Environmental Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Environmental Science Collection MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ)
DatabaseTitle	CrossRef PubMed Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition Agricultural Science Collection Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Agricultural Science Database CrossRef PubMed MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Public Health
EISSN	2036-7449
ExternalDocumentID	oai_doaj_org_article_bff0a311c887454a8acccf0e969af955 PMC7097833 32218915 10_4081_idr_2020_8543
Genre	Journal Article
GroupedDBID	--- 53G 5VS 67V 7X2 7X7 8C1 8FI 8FJ AAYXX ABDBF ABUWG ACUHS ADBBV AFFHD AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS ATCPS BAEHF BAWUL BCNDV BENPR BHPHI CCPQU CITATION DIK E3Z EBD ESX F5P FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE KQ8 M0K M48 MODMG M~E OK1 P6G PATMY PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PYCSY RPM TR2 TUS UKHRP NPM 3V. 7XB 8FE 8FH 8FK AZQEC COVID DWQXO GNUQQ K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c586t-4b1e2ec7e5687fb7b00aa524a50a6303488c97f8a6be9c087cd106920ab6dfeb3
IEDL.DBID	7X7
ISICitedReferencesCount	122
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000529834100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2036-7449 2036-7430
IngestDate	Mon Nov 10 04:32:29 EST 2025 Tue Nov 04 01:58:18 EST 2025 Fri Jul 11 09:51:57 EDT 2025 Tue Oct 07 07:07:52 EDT 2025 Thu Jan 02 22:57:37 EST 2025 Tue Nov 18 22:16:26 EST 2025 Sat Nov 29 04:08:27 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	COVID-19 SARS-CoV-2 Treatment
Language	English
License	https://creativecommons.org/licenses/by/4.0 Copyright: the Author(s), 2020. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c586t-4b1e2ec7e5687fb7b00aa524a50a6303488c97f8a6be9c087cd106920ab6dfeb3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conflict of interest: The authors declare no potential conflict of interest.
ORCID	0000-0002-2585-7567
OpenAccessLink	https://www.proquest.com/docview/2437317543?pq-origsite=%requestingapplication%
PMID	32218915
PQID	2437317543
PQPubID	4770003
ParticipantIDs	doaj_primary_oai_doaj_org_article_bff0a311c887454a8acccf0e969af955 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7097833 proquest_miscellaneous_2384210035 proquest_journals_2437317543 pubmed_primary_32218915 crossref_citationtrail_10_4081_idr_2020_8543 crossref_primary_10_4081_idr_2020_8543
PublicationCentury	2000
PublicationDate	2020-03-17
PublicationDateYYYYMMDD	2020-03-17
PublicationDate_xml	– month: 03 year: 2020 text: 2020-03-17 day: 17
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Basel
PublicationTitle	Infectious disease reports
PublicationTitleAlternate	Infect Dis Rep
PublicationYear	2020
Publisher	MDPI AG PAGEPress Publications, Pavia, Italy
Publisher_xml	– name: MDPI AG – name: PAGEPress Publications, Pavia, Italy
References	(ref4) 2020 Huang (ref8) 2020; 395 ref36 Chan (ref29) 2015; 212 Shang (ref38) 2020 Sheahan (ref14) 2020; 11 (ref2) 2020 Yan (ref22) 2013; 23 Khemani (ref20) 2015; 16 Momattin (ref11) 2019; 30 Xiaoling (ref41) 2020 Subbe (ref44) 2001; 94 Sheahan (ref32) 2020; 11 Lim (ref31) 2020; 35 (ref5) 2020 Chu (ref27) 2004; 59 Han (ref30) 2020 Chu (ref9) 2004; 59 Wang (ref12) de Wit (ref33) 2020; pii Agostini (ref34) 2018; 9 (ref43) 2018 Xu (ref40) 2020 Holshue (ref35) 2020; 382 Le (ref37) 2018; 23 (ref26) 2020; 43 Riviello (ref19) 2016; 193 Vincent (ref21) 2005; 2 Wang (ref39) 2020 (ref3) 2020 Lu (ref7) (ref16) 2020 Chan (ref28) 2003; 9 Riegler (ref42) 2019; 15 Yao (ref24) 2020 (ref1) 2020 Momattin (ref10) 2013; 17 Wang (ref6) Wang (ref23) 2020 Lai (ref15) 2020 (ref18) 2012; 307 Gao (ref25) 2020 Zhao (ref17) 2020; 43 Holshue (ref13) 2020
References_xml	– volume: 11 start-page: 222 year: 2020 ident: ref14 article-title: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV publication-title: Nat Commun doi: 10.1038/s41467-019-13940-6 – volume: 59 start-page: 252 year: 2004 ident: ref27 article-title: Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings publication-title: Thorax doi: 10.1136/thorax.2003.012658 – year: 2020 ident: ref30 article-title: The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019 publication-title: J Med Virol doi: 10.1002/jmv.25711 – volume: 15 start-page: 323 year: 2019 ident: ref42 article-title: Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy publication-title: Therapeut Clin Risk Manag doi: 10.2147/TCRM.S150524 – volume: 2 start-page: 69 year: 2005 ident: ref21 article-title: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread publication-title: J Virol doi: 10.1186/1743-422X-2-69 – year: 2020 ident: ref40 article-title: Pathological findings of COVID-19 associated with acute respiratory distress syndrome publication-title: Lancet Resp Med doi: 10.1016/S2213-2600(20)30076-X – year: 2020 ident: ref13 article-title: First Case of 2019 Novel Coronavirus in the United States publication-title: N Engl J Med doi: 10.1056/NEJMoa2001191 – ident: ref6 article-title: Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment publication-title: Biosci Trends 2020 Feb 9 – volume: 43 start-page: E007 year: 2020 ident: ref17 article-title: Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia publication-title: Zhonghua Jie He He Hu Xi Za Zhi – year: 2018 ident: ref43 article-title: Assessment Report. RoActemra publication-title: Procedure No. EMEA/H/C/000955/II/0078 – ident: ref7 article-title: Drug treatment options for the 2019- new coronavirus (2019-nCoV) publication-title: Biosci Trends 2020 Jan 28 – volume: 35 start-page: e79 year: 2020 ident: ref31 article-title: Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR publication-title: J Korean Med Sci doi: 10.3346/jkms.2020.35.e79 – year: 2020 ident: ref39 article-title: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China publication-title: JAMA doi: 10.1001/jama.2020.1585 – volume: 307 start-page: 2526 year: 2012 ident: ref18 article-title: Acute respiratory distress syndrome: the Berlin Definition publication-title: JAMA – volume: 193 start-page: 52 year: 2016 ident: ref19 article-title: Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201503-0584OC – year: 2020 ident: ref5 article-title: Interim Infection Prevention and Control Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or Persons Under Investigation for COVID-19 in Healthcare Settings publication-title: Updated February 21 – year: 2020 ident: ref25 article-title: Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies publication-title: Biosci Trends doi: 10.5582/bst.2020.01047 – volume: 382 start-page: 929 year: 2020 ident: ref35 article-title: First Case of 2019 Novel Coronavirus in the United States publication-title: N Engl J Med doi: 10.1056/NEJMoa2001191 – year: 2020 ident: ref16 article-title: NIH clinical trial of remdesivir to treat COVID-19 begins publication-title: Study enrolling hospitalized adults with COVID-19 in Nebraska – volume: 30 start-page: 9 year: 2019 ident: ref11 article-title: A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) publication-title: Travel Med Infect Dis doi: 10.1016/j.tmaid.2019.06.012 – start-page: 105924 year: 2020 ident: ref15 article-title: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease- 2019 (COVID-19): The epidemic and the challenges publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2020.105924 – volume: pii start-page: 201922083 year: 2020 ident: ref33 article-title: Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection publication-title: Proc Natl Acad Sci USA – volume: 17 start-page: e792 year: 2013 ident: ref10 article-title: Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)—possible lessons from a systematic review of SARS-CoV therapy publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2013.07.002 – year: 2020 ident: ref41 article-title: Effective Treatment of Severe COVID-19 Patients with Tocilizumab – ident: ref12 article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro publication-title: Cell Res 2020 Feb 4 – volume: 43 start-page: E019 year: 2020 ident: ref26 article-title: [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia] publication-title: Zhonghua Jie He He Hu Xi Za Zhi – volume: 11 start-page: 222 year: 2020 ident: ref32 article-title: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS CoV publication-title: Nat Commun doi: 10.1038/s41467-019-13940-6 – ident: ref36 – volume: 23 start-page: 943 year: 2018 ident: ref37 article-title: FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell induced severe or life threatening cytokine release syndrome publication-title: The Oncologist doi: 10.1634/theoncologist.2018-0028 – volume: 395 start-page: 497 year: 2020 ident: ref8 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – year: 2020 ident: ref23 article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro publication-title: Cell Res – year: 2020 ident: ref38 article-title: On the use of corticosteroids for 2019-nCoV pneumonia publication-title: The Lancet doi: 10.1016/S0140-6736(20)30361-5 – year: 2020 ident: ref2 article-title: Direzione Generale della Prevenzione Sanitaria. Ufficio 5: Prevenzione delle Malattie Trasmissibili e Profilassi Internazionale. Aggiornamento Circolare 09.03.2020. Allegato 1 publication-title: Definizione di caso di COVID-19 per la segnalazione – volume: 23 start-page: 300 year: 2013 ident: ref22 article-title: Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model publication-title: Cell Res doi: 10.1038/cr.2012.165 – volume: 9 start-page: e00221 year: 2018 ident: ref34 article-title: Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease publication-title: mBio doi: 10.1128/mBio.00221-18 – volume: 94 start-page: 521 year: 2001 ident: ref44 article-title: Validation of a modified Early Warning Score in medical admissions publication-title: QJM doi: 10.1093/qjmed/94.10.521 – year: 2020 ident: ref4 article-title: An agency of the European Union publication-title: Case definition for EU surveillance of COVID-19, as of 25 February – year: 2020 ident: ref24 article-title: In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa237 – volume: 16 start-page: S23 year: 2015 ident: ref20 article-title: Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference publication-title: Pediatr Crit Care Med doi: 10.1097/PCC.0000000000000432 – year: 2020 ident: ref3 article-title: Global Surveillance for human infection with coronavirus disease (COVID-2019) publication-title: Revised guidance, 27 February – volume: 59 start-page: 252 year: 2004 ident: ref9 article-title: Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings publication-title: Thorax doi: 10.1136/thorax.2003.012658 – volume: 9 start-page: 399 year: 2003 ident: ref28 article-title: Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study publication-title: Hong Kong Med J – year: 2020 ident: ref1 article-title: Rapid Risk Assessment: Novel coronavirus disease 2019 (COVID-2019) pandemic: increased transmission in the EU/EEA – sixth update publication-title: ECDC: Stockholm; – volume: 212 start-page: 1904 year: 2015 ident: ref29 article-title: Treatment With Lopinavir/Ritonavir or Interferon- β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset publication-title: J Infect Dis doi: 10.1093/infdis/jiv392
SSID	ssj0000396473
Score	2.5075018
Snippet	On January 9th, 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further... On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified... On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified... On January 9 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified...
SourceID	doaj pubmedcentral proquest pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	8543
SubjectTerms	Coronaviruses COVID-19 Expert Opinion Infectious diseases Pandemics Patients Public health SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Treatment Viral diseases
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQxQEJIf5ZKMhIiFOztRMnto-wpaJSVRCFqrdo4rXVlbah2mw5IA59EHi5Pgkzdhp2EYgLlxxsy3E8M5kZz8xnxl4IGXJQBjI1VfhweZE1zhWZUQpQ_YNuIqTQ0b4-ODDHx_b9ylVflBOW4IHTxm03IQgopHSGgNkVGHDOBeFtZSHYMqKXCm1XnKn4Dy6owpLCyxRoy1BNigSwqVAFbs-mhASai7EpVbGmkCJu_5-Mzd9zJleU0O5tdqu3HvmrtOo77Jpv77Kb6eiNp4qie-xbj3U950MmAEfTlKOphy0p9-q84zspNNPxy4vv-2N-eEZH6u1XaGeXFz-2-N6HyeRwzMk9PT31_dVLXZxo8u5obyeTlvegonP-K4nmPvu0--bj5G3WX7KQudJUy0w10ufeaV9WRodGoxgClLmCUkCF-g0F3FkdDFSNt04Y7aboRdpcQFNNA7riD9hG-7n1jxhHzwt0kYOVSHjhc2icCVQlEqRq0LAYsa2rna5dj0BOF2HMa_REiDAoiIuaCFMTYUbs5TD8LEFv_G3gayLbMIgQs2MD8lHd81H9Lz4asc0rote9GHc1oTWSgUXveD50owBSVAVaj9Sq0eZR6DeLAqd4mHhkWAn-LaWxEnv0GvesLXW9p52dRJBvHQtsisf_49uesBu0WZQ6J_Um21guzv1Tdt19Wc66xbMoOT8BAA0e7w priority: 102 providerName: Directory of Open Access Journals
Title	National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management
URI	https://www.ncbi.nlm.nih.gov/pubmed/32218915 https://www.proquest.com/docview/2437317543 https://www.proquest.com/docview/2384210035 https://pubmed.ncbi.nlm.nih.gov/PMC7097833 https://doaj.org/article/bff0a311c887454a8acccf0e969af955
Volume	12
WOSCitedRecordID	wos000529834100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: M0K dateStart: 20090901 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: PATMY dateStart: 20090901 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: BENPR dateStart: 20090901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: 7X7 dateStart: 20090901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database (NC LIVE) customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: 8C1 dateStart: 20090901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2036-7449 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000396473 issn: 2036-7449 databaseCode: PIMPY dateStart: 20090901 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLdg44CE-P4ojMpIiBPp7MSJnRNi3SYq1hJtMHWnyHEcqNSlpek4wGV_CPxz-0t4L3EzioALFx9iK3Ly3vP79O8R8pzxwtdCaU_kAgbjB15mTOApITSofy2zGlLo-ECORmo8jhMXcKtcWeXqTKwP6nxmMEa-jcB5qOtE8Gr-2cOuUZhddS00rpJNbJuNfC7Hso2xsADvWWKSGdNtHihL1sBsClCE25Mc8UB91lOhCNbUUo3e_yeT8_fKyV9U0f6t__2I2-SmM0Lp64Zr7pArtrxLbjQRPNpcTLpHvjnI7CltCwooWLgULEZ40pRwnVV0t8nwVPTi_PtBjx7NMTJfftXl5OL8Bx0c9vtHPYpO7umpdQ2cqvo9_XfHg12Px9RBk07pZSnOffJhf-99_43nWjV4JlTR0hMZt7410oaRkkUmQZi1Dn2hQ6Yj0JJwTJhYFkpHmY0NU9Lk4IvGPtNZlBfg0D8gG-WstI8IBf9Ny8DXMQf2YdbXmVEF3jUpuMjAPOmQlytKpcbhmGM7jWkK_gwSFsR5kSJhUyRsh7xol88bAI-_LdxBsreLEHe7fjBbfEydGKdZUTAdcG4UtgkQWmljTMFsHMW6iMOwQ7ZWhE_dYVCll1TvkGftNIgx5mZ0aYFYKVhOArxvFsArHjY81u4EzlyuYg4zco371ra6PlNOPtVQ4bK-phM8_ve2npDr-BuwtI7LLbKxXJzZp-Sa-bKcVItuLVP1qGBUfd4lmzt7o-SwWwcwYByytzCOkiHMJINhcvIT3Sgztw
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFAkkxPsRKLBIwAmnXnvtXR8QgoSqUdNQ0YfKyaw3a4iUOiFOQcClPwT-Aj-qv4QZ23EJAm49cPHBu7LW9rfz2Jn5BuChy1NPC6UdMRB4MZ7vJMb4jhJCo_rXMikohfZ6st9X-_vR1hL8mNfCUFrlXCYWgnowNnRGvkrEeaTrhP9s8sGhrlEUXZ230ChhsWE_f0KXLX_a7eD_feR5ay932utO1VXAMYEKZ45IuPWskTYIlUwTibjTOvCEDlwdokBHRJtIpkqHiY2Mq6QZoNsUea5OwkGKvic-9wwsCwJ7A5a3uptbb-pTHdenyk4Ka1OAz0H17JbEngJV7-pwQAyknttSgfAXFGHRL-BPRu7vuZq_KL-1S__bZ7sMFyszmz0v98UVWLLZVbhQnlGysvTqGnytSMFHrE6ZYGjDM7SJ8U6ZpHaYs04Zw8rZ8dG3XottTyj2kH3R2fD46Dvrvm63t1uM3PiDA1u1qMqL57Rf7XU7Do9YRb46YifJRtdh91Te_wY0snFmbwFDD1VL39MRxw3iWk8nRqVUTZNykaAB1oQnc2TEpmJqp4Yhoxg9NgISCqxpTECKCUhNeFxPn5QUJX-b-IJgVk8iZvHixnj6Lq4EVZykqat9zo2iRghCK22MSV0bhZFOoyBowsocaHEl7vL4BGVNeFAPo6Ci6JPOLP6sGG1D4XGKXDfhZonpeiWoVbiKOI7IBbQvLHVxJBu-L8jQZVGI5N_-97Luw7n1nc1e3Ov2N-7AefoklEjI5Qo0ZtNDexfOmo-zYT69V-1oBm9Pezf8BCtgix0
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NjtMwELaWLkJIiP-fwgJGAk6kjR0ndg4IQUtFtaVULKyWU3BcGyp109LsgoDLPgi8CI-zT8JMkmYpAm574JJDbEVO8s2fZ_wNIXd95rgWSntiLOBieOClxgSeEkKD-dcyLSiFtgdyOFQ7O_FojfxYnoXBssqlTiwU9XhmcI-8jcR5aOtE0HZVWcSo23s0_-BhBynMtC7baZQQ2bSfP0H4lj_sd-Ff3-O89_RV55lXdRjwTKiiPU-kzHJrpA0jJV0qAYNah1zo0NcRKHdAt4mlUzpKbWx8Jc0YQqiY-zqNxg7iUHjuCbIOLrngDbI-6j8fval3ePwAT3liihuTfR6Yar8k-RRghtuTMbKRcr-lQhGsGMWid8CfHN7f6zZ_MYS9c__zJzxPzlbuN31cyssFsmazi-RMuXdJyyNZl8jXiix8SutSCgq-PQVfGe6UxWv7Oe2Wua2cHh58G7To1hxzEtkXnU0OD77T_stOZ6tFMbzf3bVV66q8eE7nxXa_67GYVqSsU3pUhHSZvD6W979CGtkss9cIhchVy4DrmIHg-Jbr1CiHp2wcEyk4Zk3yYImSxFQM7thIZJpAJIegAkW2SBBUCYKqSe7X0-cldcnfJj5ByNWTkHG8uDFbvEsqBZakzvk6YMwobJAgtNLGGOfbOIq1i8OwSTaWoEsqNZgnR4hrkjv1MCgwzErpzMLPSsBnFJxhRrtJrpb4rlcC1oapmMGIXEH-ylJXR7LJ-4IkXRYHlILr_17WbXIKRCAZ9IebN8hp_CJYX8jkBmnsLfbtTXLSfNyb5ItblXBT8va4heEnoTST3Q
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=National+Institute+for+the+Infectious+Diseases+%E2%80%9CL.+Spallanzani%E2%80%9D+IRCCS.+Recommendations+for+COVID-19+Clinical+Management&rft.jtitle=Infectious+disease+reports&rft.au=Nicastri%2C+Emanuele&rft.au=Petrosillo%2C+Nicola&rft.au=Tommaso+Ascoli+Bartoli&rft.au=Lepore%2C+Luciana&rft.date=2020-03-17&rft.pub=MDPI+AG&rft.issn=2036-7430&rft.eissn=2036-7449&rft.volume=12&rft.issue=1&rft_id=info:doi/10.4081%2Fidr.2020.8543&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2036-7449&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2036-7449&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2036-7449&client=summon